<DOC>
	<DOCNO>NCT00124098</DOCNO>
	<brief_summary>The purpose study assess Aranesp® administer every 4 week chronic kidney disease subject safe efficacious maintain haemoglobin level great equal 100 g/L .</brief_summary>
	<brief_title>An Evaluation Aranesp® Subjects With Anaemic Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Diagnosis chronic kidney disease expect initiate dialysis duration study Creatinine clearance great 15 less 40 mL/min estimate CockroftGault equation : Creatinine Clearance = ( 140age year ) x body weight kg/serum creatinine ( mg/dL ) x 72 . For woman , value multiply 0.85 Receiving stable every week subcutaneous dos Aranesp® . A stable dose define less equal 25 % change Aranesp® dose 6week period immediately prior enrollment 1 miss dose period At least two haemoglobin value within target range 100 130 g/L obtain least 1 week apart within 5 week baseline visit Subjects must haemoglobin 100 130 g/L eligibility/baseline Serum ferritin great equal 100 mg/L transferrin saturation great equal 19.5 % Serum vitamin B12 folate level must lower limit normal range local laboratory Before study specific procedure perform , subject must provide informed consent participation study Anticipating , schedule , prior recipient kidney transplant Uncontrolled hypertension ( blood pressure great 160/100 mmHg eligibility/baseline period 2 separate measurement ) Congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) Clinical evidence severe hyperparathyroidism ( parathyroid hormone level great 1500 pg/mL biopsyproven bone marrow fibrosis ) Major surgery within 12 week enrollment ( exclude vascular access surgery ) Active chronic inflammatory process Currently receive antibiotic therapy systemic infection ALT AST great 2 time upper limit normal range Known positive HIV antibody positive hepatitis B surface antigen Clinical evidence current malignancy and/or receive systemic chemotherapy/radiotherapy exception basal cell squamous cell carcinoma skin cervical intraepithelial neoplasia Red blood cell transfusion within 8 week eligibility visit active bleeding Systemic hematologic disease ( e.g. , sickle cell anaemia , myelodysplastic syndrome , hematologic malignancy , myeloma , haemolytic anaemia ) Psychiatric disorder may impact ( judgment Investigator ) ability give inform consent participation study Pregnant breast feed woman All subject must practice adequate contraception judgment Investigator , course participation trial Previous entry study Treatment investigational agent Aranesp® device within 30 day first dose study drug schedule receive investigational agent specify protocol course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Chronic Kidney Disease ( CKD )</keyword>
	<keyword>anemia , clinical trial</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>Aranesp®</keyword>
	<keyword>Amgen</keyword>
</DOC>